Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma - Poll - MDSpire

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  • By

  • Yetian Dong

  • Tingting Yang

  • Mengyu Zhao

  • Fengmei Song

  • Rongrong Chen

  • Mingming Zhang

  • Ruimin Hong

  • Jingjing Feng

  • Shan Fu

  • Pingnan Xiao

  • Huijun Xu

  • Jiazhen Cui

  • Simao Huang

  • Guoqing Wei

  • Alex H. Chang

  • He Huang

  • Yongxian Hu

  • August 20, 2025

  • 0 min

Share

Original Source(s)

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

  • by Yetian Dong, Tingting Yang, Mengyu Zhao, Fengmei Song, Rongrong Chen, Mingming Zhang, Ruimin Hong, Jingjing Feng, Shan Fu, Pingnan Xiao, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

  • August 20, 2025

Related Content

Trends and Key Areas of Research on Artificial Intelligence in Lymphoma: A Bibliometric Study from 2010 to 2024

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • by

  • February 9, 2026

  • 3 min
Case Study: The Intersection of Chediak–Higashi Syndrome and Lymphoproliferative Disease Linked to Inborn Errors of Immunity